<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        4-5082-17
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2017
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        CIGAVEL PLUS 300/12.5 mg Film Coated Tablet
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        HYDROCHLOROTHIAZIDE, IRBESARTAN
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        300,12.5
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        30
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        53
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="TABUK PHARMACEUTICAL MANUFACTURING CO." />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            TABUK PHARMACEUTICAL MANUFACTURING CO.
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 359]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Cigalah Group
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            CIGALAH PHARMA
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        C09CA04
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p style="text-align:left">Cigavel Plus is a combination of two active substances, irbesartan and<br />hydrochlorothiazide.<br />Irbesartan belongs to a group of medicines known as angiotensin-II receptor<br />antagonists. Angiotensin-II is a substance produced in the body that binds to<br />receptors in blood vessels causing them to tighten. This results in an increase<br />in blood pressure. Irbesartan prevents the binding of angiotensin-II to these<br />receptors, causing the blood vessels to relax and the blood pressure to lower.<br />Hydrochlorothiazide is one of a group of medicines (called thiazide diuretics)<br />that causes increased urine output and so causes a lowering of blood pressure.<br />The two active ingredients in Cigavel Plus work together to lower blood<br />pressure further than if either was given alone.<br />Cigavel Plus is used to treat high blood pressure, when treatment with<br />irbesartan or hydrochlorothiazide alone did not provide adequate control of<br />your blood pressure.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p style="text-align:left">Do not take Cigavel Plus<br />- If you are allergic to irbesartan or any of the other ingredients of this<br />medicine.<br />- If you are allergic to hydrochlorothiazide or any other sulfonamide-derived<br />medicines.<br />- If you are more than 3 months pregnant. (It is also better to avoid<br />Cigavel Plus in early pregnancy).<br />- If you have severe liver or kidney problems.<br />- If you have difficulty in producing urine.<br />- If your doctor determines that you have persistently high calcium or low<br />potassium levels in your blood.<br />Children and adolescents<br />Cigavel Plus should not be given to children and adolescents (under 18 years).<br />Take special care with Cigavel Plus<br />Talk to your doctor before taking Cigavel Plus and if any of the following<br />apply to you:<br />- If you get excessive vomiting or diarrhea.<br />- If you suffer from kidney problems or have a kidney transplant.<br />- If you suffer from heart problems.<br />- If you suffer from liver problems.<br />- If you suffer from diabetes.<br />- If you suffer from lupus erythematosus (also known as lupus or SLE).<br />- If you suffer from primary aldosteronism (a condition related to high<br />production of the hormone aldosterone, which causes sodium retention and,<br />in turn, an increase in blood pressure).<br />You must tell your doctor if you think you are (or might become) pregnant.<br />Cigavel Plus is not recommended in early pregnancy, and must not be taken if<br />you are more than 3 months pregnant, as it may cause serious harm to your<br />baby if used at that stage.<br />You should also tell your doctor:<br />- If you are on a low-salt diet.<br />- If you have signs such as abnormal thirst, dry mouth, general weakness,<br />drowsiness, muscle pain or cramps, nausea, vomiting, or an abnormally<br />fast heart beat which may indicate an excessive effect of<br />hydrochlorothiazide (contained in Cigavel Plus).<br />- If you experience an increased sensitivity of the skin to the sun with<br />symptoms of sunburn (such as redness, itching, swelling, blistering)<br />occurring more quickly than normal.<br />- If you are going to have an operation (surgery) or be given anaesthetics.<br />- If you have changes in your vision or pain in one or both of your eyes<br />while taking Cigavel Plus. This could be a sign that you are developing<br />glaucoma, increased pressure in your eye(s). You should discontinue<br />Cigavel Plus treatment and seek medical attention.<br />The hydrochlorothiazide contained in this medicine could produce a positive<br />result in an anti-doping test.<br />Taking other medicines<br />Tell your doctor or pharmacist if you are taking, have recently taken or might<br />take any other medicines.<br />Diuretic agents such as the hydrochlorothiazide contained in Cigavel Plus<br />may have an effect on other medicines. Preparations containing lithium should<br />not be taken with Cigavel Plus without close supervision by your doctor.<br />You may need to have blood checks if you take:<br />- Potassium supplements.<br />- Salt substitutes containing potassium.<br />- Potassium sparing medicines or other diuretics (water tablets).<br />- Some laxatives.<br />- Medicines for the treatment of gout.<br />- Therapeutic vitamin D supplements.<br />- Medicines to control heart rhythm.<br />- Medicines for diabetes (oral agents or insulins).<br />- Carbamazepine (a medicine for the treatment of epilepsy).<br />It is also important to tell your doctor if you are taking other medicines to<br />reduce your blood pressure, steroids, medicines to treat cancer, pain killers,<br />arthritis medicines, or colestyramine and colestipol resins for lowering blood<br />cholesterol.<br />Taking Cigavel Plus with food and drink<br />Cigavel Plus can be taken with or without food.<br />Due to the hydrochlorothiazide contained in Cigavel Plus, if you drink alcohol<br />while on treatment with this medicine, you may have an increased feeling of<br />dizziness on standing up, specially when getting up from a sitting position.<br />Pregnancy, breast-feeding and fertility<br />Pregnancy<br />You must tell your doctor if you think you are (or might become) pregnant.<br />Your doctor will normally advise you to stop taking Cigavel Plus before you<br />become pregnant or as soon as you know you are pregnant and will advise you<br />to take another medicine instead of Cigavel Plus. Cigavel Plus is not<br />recommended during pregnancy, and must not be taken when more than 3<br />months pregnant, as it may cause serious harm to your baby if used after the<br />third month of pregnancy.<br />Breast-feeding<br />Tell your doctor if you are breast-feeding or about to start breast-feeding.<br />Cigavel Plus is not recommended for mothers who are breast-feeding, and<br />your doctor may choose another treatment for you if you wish to breast-feed,<br />especially if your baby is newborn, or was born prematurely.<br />Driving and using machines<br />No studies on the effects on the ability to drive and use machines have been<br />performed. Cigavel Plus is unlikely to affect your ability to drive or use<br />machines. However, occasionally dizziness or weariness may occur during<br />treatment of high blood pressure. If you experience these, talk to your doctor<br />before attempting to drive or use machines.<br />Important information about some of the ingredients of Cigavel Plus<br />Cigavel Plus contains lactose. If you have been told by your doctor that you<br />have an intolerance to some sugars (e.g. lactose), contact your doctor before<br />taking this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p style="text-align:left">Always take Cigavel Plus exactly as your doctor has told you. Check with<br />your doctor or pharmacist if you are not sure.<br />Dosage<br />The recommended dose of Cigavel Plus is one or two tablets a day. Cigavel<br />Plus will usually be prescribed by your doctor when your previous treatment<br />did not reduce your blood pressure enough. Your doctor will instruct you how<br />to switch from the previous treatment to Cigavel Plus.<br />Method of administration<br />Cigavel Plus is for oral use. Swallow the tablets with a sufficient amount of<br />fluid (e.g. one glass of water). You can take Cigavel Plus with or without<br />food. Try to take your daily dose at about the same time each day. It is<br />important that you continue to take Cigavel Plus until your doctor tells you<br />otherwise.<br />The maximal blood pressure lowering effect should be reached 6-8 weeks after<br />beginning treatment.<br />If you take more Cigavel Plus than you should<br />If you accidentally take too many tablets, contact your doctor immediately.<br />Children should not take Cigavel Plus<br />Cigavel Plus should not be given to children under 18 years of age. If a child<br />swallows some tablets, contact your doctor immediately.<br />If you forget to take Cigavel Plus<br />If you accidentally miss a daily dose, just take the next dose as normal. Do not<br />take a double dose to make up for a forgotten dose.<br />If you have any further questions on the use of this medicine, ask your doctor<br />or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p style="text-align:left">Like all medicines, this medicine can cause side effects, although not<br />everybody gets them.<br />Some of these effects may be serious and may require medical attention.<br />Rare cases of allergic skin reactions (rash, urticaria), as well as localised<br />swelling of the face, lips and/or tongue have been reported in patients taking<br />irbesartan.<br />If you get any of the above symptoms or get short of breath, stop taking<br />Cigavel Plus and contact your doctor immediately.<br />Side effects reported in clinical studies for patients treated with Cigavel Plus<br />were:<br />Common side effects (affect 1 to 10 users in 100)<br />- Nausea/vomiting.<br />- Abnormal urination.<br />- Fatigue.<br />- Dizziness (including when getting up from a lying or sitting position).<br />- Blood tests may show raised levels of an enzyme that measures the muscle<br />and heart function (creatine kinase) or raised levels of substances that<br />measure kidney function (blood urea nitrogen, creatinine).<br />If any of these side effects causes you problems, talk to your doctor.<br />Uncommon side effects (affect 1 to 10 users in 1,000)<br />- Diarrhea.<br />- Low blood pressure.<br />- Fainting.<br />- Heart rate increased.<br />- Flushing.<br />- Swelling.<br />- Sexual dysfunction (problems with sexual performance).<br />- Blood tests may show lowered levels of potassium and sodium in your<br />blood.<br />If any of these side effects causes you problems, talk to your doctor.<br />Side effects reported since the launch of Cigavel Plus<br />Some undesirable effects have been reported since marketing of Cigavel Plus.<br />Undesirable effects where the frequency is not known are: Headache, ringing<br />in the ears, cough, taste disturbance, indigestion, pain in joints and muscles,<br />liver function abnormal and impaired kidney function, increased level of<br />potassium in your blood and allergic reactions such as rash, hives, swelling of<br />the face, lips, mouth, tongue or throat. Uncommon cases of jaundice<br />(yellowing of the skin and/or whites of the eyes) have also been reported.<br />As for any combination of two active substances, side effects associated with<br />each individual component cannot be excluded.<br />Side effects associated with irbesartan alone<br />In addition to the side effects listed above, chest pain has also been reported.<br />Side effects associated with hydrochlorothiazide alone<br />Loss of appetite; stomach irritation; stomach cramps; constipation; jaundice<br />(yellowing of the skin and/or whites of the eyes); inflammation of the pancreas<br />characterised by severe upper stomach pain, often with nausea and vomiting;<br />sleep disorders; depression; blurred vision; lack of white blood cells, which<br />can result in frequent infections, fever; decrease in the number of platelets (a<br />blood cell essential for the clotting of the blood), decreased number of red<br />blood cells (anemia) characterised by tiredness, headaches, being short of<br />breath when exercising, dizziness and looking pale; kidney disease; lung<br />problems including pneumonia or build-up of fluid in the lungs; increased<br />sensitivity of the skin to the sun; inflammation of blood vessels; a skin disease<br />characterized by the peeling of the skin all over the body; cutaneous lupus<br />erythematosus, which is identified by a rash that may appear on the face, neck,<br />and scalp; allergic reactions; weakness and muscle spasm; altered heart rate;<br />reduced blood pressure after a change in body position; swelling of the<br />salivary glands; high sugar levels in the blood; sugar in the urine; increases in<br />some kinds of blood fat; high uric acid levels in the blood, which may cause<br />gout.<br />It is known that side effects associated with hydrochlorothiazide may increase<br />with higher doses of hydrochlorothiazide.<br />If you get any side effects, talk to your doctor or pharmacist. This includes<br />any possible side effects not listed in this leaflet.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p style="text-align:left">Keep out of reach of children.<br />Store below 30&deg;C.<br />Do not use beyond the expiry date or if the product shows any sign of<br />deterioration.<br />Do not throw away any medicines via wastewater or household waste. Ask<br />your pharmacist how to throw away the medicines you no longer use. These<br />measures will help to protect environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p style="text-align:left">Cigavel Plus 150/12.5 mg: Each film coated tablet contains: Irbesartan 150<br />mg and Hydrochlorothiazide 12.5 mg.<br />Cigavel Plus 300/12.5 mg: Each film coated tablet contains: Irbesartan 300<br />mg and Hydrochlorothiazide 12.5 mg.<br />Cigavel Plus 300/25 mg: Each film coated tablet contains: Irbesartan 300 mg<br />and Hydrochlorothiazide 25 mg.<br />Excipients: Lactose, croscarmellose sodium, microcrystalline cellulose,<br />colloidal silicon dioxide, magnesium stearate, HPMC, PEG, titanium dioxide,<br />ferric oxide red, ferric oxide yellow and simethicone.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Packs of 30 Film Coated Tablets.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p style="text-align:left">Manufactured by: Tabuk Pharmaceutical Manufacturing CO.,<br />Madina Road, P.O. Box 3633, Tabuk-Saudi Arabia.<br />For: Cigalah Pharma, Jeddah-Saudi Arabia.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                June 2015
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>سقاڤيل بلس هو دواء مركب من مادتين فعالتين، إربيسارتان و هيدروكلوروثيازيد.<br />. ينتمي إربيسارتان إلى مجموعة من الأدوية تعرف بمضادات مستقبل الأنجيوتنسين 2<br />الأنجيوتنسين 2 هو عبارة عن مادة يتم إنتاجها في الجسم ترتبط بمستقبلاتها في الأوعية<br />الدموية مؤدية إلى انقباضها وهذا يؤدي إلى ارتفاع ضغط الدم. يعمل إربيسارتان على منع<br />ارتباط الأنجيوتنسين 2 بهذه المستقبلات، مما يؤدي إلى إرخاء الأوعية الدموية و انخفاض<br />ضغط الدم.<br />ينتمي هيدروكلوروثيازيد إلى مجموعة من الأدوية (تعرف بمدرات البول الثيازيدية) التي<br />تعمل على زيادة كمية البول المخرجة مما يؤدي إلى انخفاض ضغط الدم.<br />تعمل كلا المادتين الفعاتين في سقاڤيل بلس معا على تخفيض ضغ ط الد م أكث ر مم ا لو<br />أعطيت كل منهما لوحدها.<br />يستعمل سقاڤيل بلس لعلاج ارتفاع ضغظ الدم عندما يكون العلاج بأي من إربيسارتان أو<br />هيدروكلوروثيازيد لوحده لا يحقق السيطرة الكافية على ضغط الدم.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>موانع استعمال سقاڤيل بلس<br />- إذا كنت تعاني من الحساسية لإربيسارتان أو لأي مكونات أخرى في هذا الدواء.<br />- إذ ا كن ت تعان ي م ن الحساسية لهيدروكلوروثيازيد أ و لأ ي أدوية أخرى من مشتقات<br />سلفوناميد.<br />- إذا كنت حامل وعمر الحمل يزيد عن 3 شهور. (يفضل أيضا تجنب تناول سقاڤيل بلس<br />خلال الأشهر الثلاث الأولى من الحمل).<br />- إذا كنت تعاني من مشاكل حادة في الكبد أو الكلى.<br />- إذا كنت تعاني من صعوبة في التبول.<br />- إذ ا حد د طبيب ك أن ك تعان ي م ن ارتفاع في مستويات الكالسيوم أو انخفاض مستويات<br />البوتاسيوم بشكل مستمر في الدم.<br />الأطفال والمراهقون<br />يجب عدم إعطاء سقاڤيل بلس للأطفال والمراهقين (الأقل من 18 عاما)ً.<br />الاحتياطات عند تناول سقاڤيل بلس<br />تحدث إلى الطبيب قبل تناول سقاڤيل بلس و إذا كان أي من التالي ينطبق عليك:<br />- إذا كنت تعاني من قيء أو إسهال شديد.<br />- إذا كنت تعاني من مشاكل في الكلى أو خضعت لعملية زرع الكلى.<br />- إذا كنت تعاني من مشاكل في القلب.<br />- إذا كنت تعاني من مشاكل في الكبد.<br />- إذا كنت تعاني من داء السكري.<br />- إذا كنت تعاني من ذأب حمامى (يعرف أيضا بالذأب أو ذأب حمامى جهازي).<br />- إذا كنت تعاني من مرض يسمى ألدوسيتونية أولية (حالة مرتبطة بزيادة انتاج هرمون<br />الألدوستيرون، الذي يؤدي إلى احتباس الصوديوم، و بالتالي، ارتفاع ضغط الدم).<br />يجب عليك إخبار الطبيب إذا كنت تعتقدين أنك حاملا (أو من المحتمل حصول الحمل). لا<br />يوصى باستعمال سقاڤيل بلس خلال الأشهر الثلاث الأولى من الحمل ويجب عدم تناوله إذا<br />كنت حامل وعمر الحمل يزيد عن 3 شهور ، حيث ق د يؤدي استعمال ه في هذ ه الفترة إلى<br />حدوث ضرر خطير على الجنين.<br />يجب إخبار الطبيب أيضا:ً<br />- إذا كنت تخضع لحمية غذائية قليلة الملح.<br />- إذ ا كن ت تعان ي م ن علامات مث ل شعو ر غي ر طبيع ي بالعطش، جفا ف الفم ، الشعور<br />بالضعف العام، النعاس، ألم أو تشنج عضلي، الشعور بالغثيان، القيء، أو تسرع<br />نبضات القلب بشكل غير طبيعي وذلك قد يشير إلى التأثير الشديد الناتج عن<br />هيدروكلوروثيازيد (أحد مكونات سقاڤيل بلس).<br />- إذا عانيت من زيادة حساسية الجلد للشمس مع ظهور أعراض الحرق الناتج عن<br />التعرض لأشعة الشمس بشكل أسرع من الطبيعي (مثل احمرار، حكة، تورم، تنفط).<br />- إذا كنت ستخضع لعملية جراحية أو سيتم إعطاؤك مخدر.<br />- إذا كنت تعاني من تغيرات في الرؤية أو ألم في إحدى العينين أو كلاهما خلال فترة<br />تناول سقاڤيل بلس. قد تكون هذه علامة بأنك تعاني من الجلوكوما، ارتفاع الضغط في<br />إحدى العينين أ و كلاهما . يجب عليك التوقف عن تناول سقاڤيل بلس و طلب العناية<br />الطبية.<br />قد يؤدي هيدروكلوروثيازيد الذي هو أحد مكونات هذا الدواء إلى ظهور نتائج إيجابية<br />للفحص الذي يكشف تناول المنشطات.<br />تناول أدوية أخرى<br />أخبر طبيبك أو الصيدلاني إذا كنت تتناول، تناولت مؤخرا أو من المحتمل أن تتناول أي أدوية<br />أخرى.<br />قد يكون لعوامل مدرات البول مثل هيدروكلوروثيازيد الذي هو أحد مكونات سقاڤيل بلس تأثير<br />على الأدوية الأخرى. يجب عدم تناول المستحضرات المحتوية على الليثيوم بالتزامن مع<br />سقاڤيل بلس بدون الإشراف الطبي الجيد.<br />قد تحتاج للقيام بفحوصات دم إذا كنت تتناول أي مما يلي:<br />- مكملات البوتاسيوم.<br />- بدائل الملح المحتوية على البوتاسيوم.<br />- الأدوية الحافظة للبوتاسيوم أو مدرات البول الأخرى (أقراص الماء).<br />- بعض الملينات.<br />- أدوية علاج النقرس.<br />- مكملات ڤيتامين د العلاجية.<br />- أدوية لضبط سرعة نبضات القلب.<br />- أدوية لعلاج داء السكري (عوامل يتم تناولها عن طريق الفم أو الإنسولين).<br />- كاربامازيبين (دواء يستعمل لعلاج الصرع).<br />من الضروري أيضا إخبار طبيبك إذا كنت تتناول أدوية أخرى خافضة لضغط الدم،<br />ستيرويدات، أدوية لعلاج السرطان، مسكنات، أدوية لعلاج التهاب المفاصل، أو<br />كوليستيرامين و نظائر الكوليستيبول المستعملة لتخفيض مستوى الكوليستيرول في الدم.<br />تناول سقاڤيل بلس مع الطعام والشراب<br />من الممكن تناول سقاڤيل بلس مع أو بدون تناول الطعام.<br />نتيجة لاحتواء سقاڤيل بلس على هيدروكلوروثيازيد، فإنه إذا قمت بشرب الكحول خلال فترة<br />العلاج بهذا الدواء، قد تعاني من ازدياد الشعور بالدوار عند الوقوف، خصوصا عند الوقوف<br />بعد وضعية الجلوس.<br />الحمل، الإرضاع و الخصوبة<br />الحمل<br />يجب عليك إخبار الطبيب إذا كنت تعتقدين أنك حاملا (أو من المحتمل حصول الحمل).<br />سيقوم الطبيب عادة بنصحك بالتوقف عن تناول سقاڤيل بلس قبل حصول الحمل أو في حال<br />حصوله وسينصحك بتناول دواء آخر بدلا م ن سقاڤيل بلس. لا يوصى باستعمال سقاڤيل<br />بلس خلال فترة الحمل ويجب عدم تناوله إذا كنت حامل وعمر الحمل يزيد عن 3 شهور،<br />حيث قد يؤدي استعماله بعد الشهر الثالث من الحمل إلى حدوث ضررا خطيرا على الجنين.<br />الإرضاع<br />أخبري طبيبك إذا كنت ترضعين أو على وشك البدء بالإرضاع. لا يوصى باستعمال سقاڤيل<br />بلس للأمهات المرضعات، وقد يختار لك الطبيب علاج آخر إذا كنت ترغبين في الإرضاع،<br />خصوصا إذا كان طفلك حديث الولادة أو ولد قبل أوانه.<br />قيادة المركبات و استخدام الآلات<br />لا يوجد دراسات حول التأثير على القدرة على القيادة و استخدام الآلات. من غير المحتمل<br />أن يؤثر سقاڤيل بلس على قدرتك على القيادة أ و استخدا م الآلات. ولكن، قد يحدث أحيانا الشعور بدوا ر و إرها ق خلال فترة علاج ارتفاع ضغ ط الدم . إذ ا حصل لك أي م ن هذه<br />الأعراض، تحدث إلى طبيبك قبل محاولة القيام بالقيادة أو استخدام الآلات.<br />معلومات مهمة حول بعض مكونات سقاڤيل بلس<br />يحتوي سقاڤيل بلس على اللاكتوز. إذا أخبرك الطبيب أنك تعاني من عدم القدرة على تحمل<br />بعض أنواع السكريات (مثل اللاكتوز)، قم بالاتصال مع الطبيب قبل البدء بتناول هذا الدواء.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>دائما تناول سقاڤيل بلس تماما كما أخبرك الطبيب. تأكد من طبيبك أو الصيدلاني إذا لم تكن<br />متأكدا.ً<br />الجرعة<br />تبلغ الجرعة الموصى بها من سقاڤيل بلس قرص أو قرصين يوميا.ً سيصف لك الطبيب<br />سقاڤيل بلس عادة عندم ا لا يؤدي تناول علاج آخر من تخفيض ضغط الد م بشكل كافي.<br />سيرشدك الطبيب حول كيفية تغيير علاجك السابق إلى سقاڤيل بلس.<br />طريقة الاستعمال<br />يتم تناول سقاڤيل بلس عن طريق الفم. قم ببلع القرص مع شرب كمية كافية من السوائل<br />(مثل كأس واحد من الماء). ومن الممكن تناول سقاڤيل بلس مع أو دون تناول الطعام. حاول<br />أن تتناول الجرعة اليومية في نفس الوقت من كل يوم تقريبا.ً من الضروري الاستمرار في<br />تناول سقاڤيل بلس حتى يخبرك الطبيب بغير ذلك.<br />8 أسابيع من بدء - يجب الوصول إلى الحد الأقصى من التأثير الخافض لضغط الدم خلال 6<br />العلاج.<br />إذا تناولت سقاڤيل بلس أكثر مما يجب<br />إذا قمت بتناول عدد كبير من الأقراص عن طريق الخطأ، قم بالاتصال بطبيبك فور اً.<br />يجب عدم إعطاء سقاڤيل بلس للأطفال<br />يجب عد م إعطا ء سقاڤيل بلس للأطفال الأقل من 18 عاما.ً إذا قا م أحد الأطفال ببلع بعض<br />الأقراص، قم بالاتصال بالطبيب على الفور.<br />إذا نسيت تناول جرعة سقاڤيل بلس<br />إذا نسيت تناول جرعتك اليومية عن طريق الخطأ، فقط تناول الجرعة التالية كالمعتاد. لا<br />تتناول جرعة مضاعفة لتعويض الجرعة التي نسيتها.<br />إذا كان لديك أي أسئلة إضافية عن استعمال هذا الدواء، اسأل طبيبك أو الصيدلاني.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>مثل كل الأدوية، قد يسبب هذا الدواء آثارا جانبية، على الرغم من عدم حدوثها لدى الجميع.<br />قد تكون بعض هذ الآثار خطيرة وقد تحتاج إلى عناية طبية.<br />تم تسجيل حدوث حالات نادرة من التفاعلات الجلدية التحسسية (طفح، شرى)، وكذلك تورم<br />موضعي في الوجه، الشفاه و/أو اللسان عند المرضى الذين يتناولون إربيسارتان.<br />إذا حصل لديك أي من الأعراضالمذكورة في الأعلى أو حصل لديك قصر في النفس، توقف<br />عن تناول سقاڤيل بلس و اتصل مع طبيبك على الفور.<br />تم تسجيل الآثار الجانبية التالية في الدراسات السريرية على المرضى الذين تناولوا سقاڤيل<br />بلس:<br />( آثار جانبية شائعة (تؤثر على 1 إلى 10 أشخاص من كل 100<br />- الشعور بالغثيان/القيء.<br />- تبول غير طبيعي.<br />- الشعور بالتعب.<br />- الشعور بالدوار (بما فيها عند الوقوف من وضع الاستلقاء أو الجلوس).<br />- قد تظهر فحوصات الدم ارتفاع مستويات الإنزيم الذي يشير إلى سلامة وظائف القلب<br />والعضلات (إنزيم كرياتين كاينيز) أو ارتفاع مستويات المواد التي تشير إلى سلامة<br />وظيفة الكلى (يوريا نيتروجين الدم، كرياتينين).<br />إذا سبب أي من هذه الأعراض مشكلة لك، تحدث إلى طبيبك.<br />( آثار جانبية غير شائعة (تؤثر على 1 إلى 10 أشخاص من كل 1000<br />- إسهال.<br />- انخفاض ضغط الدم.<br />- الشعور بالإغماء.<br />- ازدياد معدل سرعة نبضات القلب.<br />- احمرار الوجه.<br />- تورم.<br />- عجز جنسي (مشاكل في الأداء الجنسي).<br />- قد تظهر فحوصات الدم انخفاض مستويات البوتاسيوم والصوديوم في الدم.<br />إذا سبب حدوث أي من هذه الأعراض مشكلة لك، تحدث إلى طبيبك.<br />آثار جانبية تم تسجيلها خلال فترة تسويق سقاڤيل بلس<br />تم تسجيل بعض الآثار غير المرغوب فيها خلال فترة تسويق سقاڤيل بلس. إن الآثار غير<br />المرغوب فيها التي حدوثت بتكرار غير معروف هي: صداع ، سماع رنين في الأذنين،<br />سعال، اضطراب حاسة التذوق، عسر الهضم، ألم في المفاصل و العضلات، خلل في وظيفة<br />الكبد و الكلى، ارتفاع مستويات بوتاسيوم الدم و تفاعلات تحسسية مثل طفح، شرى، تورم<br />الوجه، الشفاه، الفم، اللسان أو الحلق (البلعوم). تم تسجيل أيضا حالات غير شائعة من<br />اليرقان (اصفرار الجلد و/أو المنطقة البيضاء في العيون).<br />كما هو الحال مع أي دواء مركب من مادتين فعالتين، لا يمكن التغاضي عن أي آثار جانبية<br />ترتبط بكل منهما بشكل مفرد.<br />الآثار الجانبية المرتبطة بإربيسارتان لوحده<br />بالإضافة إلى الآثار الجانبية المذكورة في الأعلى، تم تسجيل ألم في الصدر.<br />الآثار الجانبية المرتبطة بهيدروكلوروثيازيد لوحده<br />فقدان الشهية، تهيج و تشنج في المعدة، إمساك، يرقان (اصفرار الجلد و/أو المنطقة البيضاء<br />في العيون)، التهاب البنكرياس من أعراضه ألم حاد في أعلى المعدة، غالبا يرافقه الشعور<br />بالغثيان والقيء، اضطرابات النوم، الشعور بالاكتئاب، ضبابية الرؤية، نقص في عدد خلايا<br />الدم البيضاء، الذي يسبب التهابات متكررة، حمى ، انخفاض في عدد الصفيحات الدموية<br />(خلايا دم ضرورية لعملية تجلط الدم)، انخفاض في عدد خلايا الدم الحمراء (فقر دم) و من<br />أعراضه الشعور بالتعب، الصداع، قصر في النفس عند ممارسة التمارين الرياضية،<br />الشعور بالدوار و شحوب الوجه، مرض في الكلى، مشاكل في الرئتين تتضمن التهاب الرئة<br />أو تجمع السوائل في الرئتين، زيادة حساسية الجلد للشمس، التهاب في الأوعية الدموية،<br />مرض في الجلد و من أعراضه تقشر الجل د في جمي ع مناطق الجسم ، ذأب حمامى جلدي،<br />والذي يتم الكشف عنه من خلال الطفح الذي قد يظهر على الوجه، الرقبة، و فروة الرأس،<br />تفاعلات تحسسية، ضعف و تشنج العضلات، تغير في معدل سرعة نبضات القلب، انخفاض<br />ضغط الدم بعد تغيير وضعية الجسم، تورم الغدد اللعابية، ارتفاع مستويات السكر في الدم،<br />ظهور السكر في البول، ارتفاع مستويات بعض أنواع دهون الدم، ارتفاع مستويات حمض<br />اليوريك في الدم، والذي قد يسبب مرض النقرس.<br />من المعروف أن الآثار الجانبية المرتبطة باستعمال هيدروكلوروثيازيد قد تزداد عند<br />استعمال جرعات أعلى.<br />إذا اعانيت من أي آثار جانبية، تحدث إلى طبيبك أو الصيدلاني. هذا يتضمن أي آثار جانبية<br />غير مذكورة في هذه النشرة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>يحفظ بعيدا عن متناول الأطفال.<br />يحفظ في درجة حرارة أقل من 30 &deg;م.<br />لا تستعمل الدواء بعد انتهاء مدة صلاحيته أو عند ملاحظة أي علامة تلف فيه.<br />يجب عدم التخلص من أي أدوية عن طريق رميها في المياه العادمة أو النفايات المنزلية.<br />استشر الصيدلاني عن كيفية التخلص من الأدوية التي لم تعد تستخدمها. سوف تساعد هذه<br />التدابير في حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>12.5 ملجم: يحتوي كل قرص مغلف على: إربيسارتان 150 ملجم / سقاڤيل بلس 150<br />وهيدروكلوروثيازيد 12.5 ملجم.<br />12.5 ملجم: يحتوي كل قرص مغلف على: إربيسارتان 300 ملجم / سقاڤيل بلس 300<br />وهيدروكلوروثيازيد 12.5 ملجم.<br />25 ملجم: يحتو ي ك ل قرص مغل ف على : إربيسارتا ن 300 ملجم / سقاڤيل بلس 300<br />وهيدروكلوروثيازيد 25 ملجم.<br />السواغات: لاكتوز، كروسكارميلوز الصوديوم، ميكروكريستالين سيليلوز ، ثاني أكسيد<br />السيليكون الغروي، ستيرات المغنيسيوم، هيدروكسي بروبيل ميثيل سيليلوز، بولي إيثيلين<br />جلايكول، ثاني أكسيد التيتانيوم، أكسيد الحديد الأحمر، أكسيد الحديد الأصفر و سيميثيكون.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p>عبوات تحتوي على 30 قرصا مغلفا.ً</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>إنتاج: شركة تبوك للصناعات الدوائية،<br />طريق المدينة، ص.ب 3633 ، تبوك-المملكة العربية السعودية.<br />لصالح: شركة سقالة فارما، جدة-المملكة العربية السعودية.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            يونيو 2015
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Cigavel Plus 300 mg/12.5 mg film-coated tablets.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each film-coated tablet contains 300 mg of irbesartan and 12.5 mg of hydrochlorothiazide.
For the full list of excipients, see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Film-coated tablet.
Light pink colored, oval shaped film coated tablets, engraved with ‘KW’ on one side and plain on the other
side
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:left">Treatment of essential hypertension.<br />This fixed dose combination is indicated in adult patients whose blood pressure is not adequately controlled<br />on irbesartan or hydrochlorothiazide alone (see section 5.1).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:left">Posology<br />Cigavel Plus can be taken once daily, with or without food.<br />Dose titration with the individual components (i.e. irbesartan and hydrochlorothiazide) may be<br />recommended.<br />When clinically appropriate direct change from monotherapy to the fixed combinations may be considered:<br />&bull; Cigavel Plus 150 mg/12.5 mg may be administered in patients whose blood pressure is not adequately<br />controlled with hydrochlorothiazide or irbesartan 150 mg alone;<br />&bull; Cigavel Plus 300 mg/12.5 mg may be administered in patients insufficiently controlled by irbesartan 300<br />mg or by Cigavel Plus 150 mg/12.5 mg.<br />&bull; Cigavel Plus 300 mg/25 mg may be administered in patients insufficiently controlled by Cigavel Plus 300<br />mg/12.5 mg.<br />Doses higher than 300 mg irbesartan/25 mg hydrochlorothiazide once daily are not recommended.<br />When necessary, Cigavel Plus may be administered with another antihypertensive medicinal product (see<br />section 4.5).<br />Special Populations<br />Renal impairment: due to the hydrochlorothiazide component, Cigavel Plus is not recommended for<br />patients with severe renal dysfunction (creatinine clearance &lt; 30 ml/min). Loop diuretics are preferred to<br />thiazides in this population. No dosage adjustment is necessary in patients with renal impairment whose<br />renal creatinine clearance is &ge; 30 ml/min (see sections 4.3 and 4.4).<br />Hepatic impairment: Cigavel Plus is not indicated in patients with severe hepatic impairment. Thiazides<br />should be used with caution in patients with impaired hepatic function. No dosage adjustment of Cigavel<br />Plus is necessary in patients with mild to moderate hepatic impairment (see section 4.3).<br />Older people: no dosage adjustment of Cigavel Plus is necessary in older people.<br />Paediatric population: Cigavel Plus is not recommended for use in children and adolescents because the<br />safety and efficacy have not been established. No data are available.<br />Method of Administration<br />For oral use.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                • Hypersensitivity to the active substances or to any of the excipients listed in section 6.1, or to other
sulfonamide-derived substances (hydrochlorothiazide is a sulfonamide-derived substance)
• Second and third trimesters of pregnancy (see sections 4.4 and 4.6)
• Severe renal impairment (creatinine clearance < 30 ml/min)
• Refractory hypokalaemia, hypercalcaemia
• Severe hepatic impairment, biliary cirrhosis and cholestasis
• Co-administration of Cigavel Plus with aliskiren-containing medicines in patients with diabetes or with
moderate to severe renal impairment (glomerular filtration rate (GFR) <60 ml/min/1.73 m²) (see sections
4.4 and 4.5).
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:left">Hypotension - Volume-depleted patients: Cigavel Plus has been rarely associated with symptomatic<br />hypotension in hypertensive patients without other risk factors for hypotension. Symptomatic hypotension<br />may be expected to occur in patients who are volume and/or sodium depleted by vigorous diuretic therapy,<br />dietary salt restriction, diarrhoea or vomiting. Such conditions should be corrected before initiating therapy<br />with Cigavel Plus.<br />Renal artery stenosis - Renovascular hypertension: there is an increased risk of severe hypotension and<br />renal insufficiency when patients with bilateral renal artery stenosis or stenosis of the artery to a single<br />functioning kidney are treated with angiotensin converting enzyme inhibitors or angiotensin-II receptor<br />antagonists. While this is not documented with Cigavel Plus, a similar effect should be anticipated.<br />Renal impairment and kidney transplantation: when Cigavel Plus is used in patients with impaired renal<br />function, a periodic monitoring of potassium, creatinine and uric acid serum levels is recommended. There<br />is no experience regarding the administration of Cigavel Plus in patients with a recent kidney<br />transplantation. Cigavel Plus should not be used in patients with severe renal impairment (creatinine<br />clearance &lt; 30 ml/min) (see section 4.3). Thiazide diuretic-associated azotemia may occur in patients with<br />impaired renal function. No dosage adjustment is necessary in patients with renal impairment whose<br />creatinine clearance is &ge; 30 ml/min. However, in patients with mild to moderate renal impairment<br />(creatinine clearance &ge; 30 ml/min but &lt; 60 ml/min) this fixed dose combination should be administered<br />with caution.<br />Dual blockade of the renin-angiotensin-aldosterone system (RAAS):<br />Dual blockade of the RAAS by combining Cigavel Plus with aliskiren or with angiotensin-converting<br />enzyme inhibitors (ACEI) is not recommended since there is an increased risk of hypotension,<br />hyperkalaemia, and changes in renal function. The use of Cigavel Plus in combination with aliskiren is<br />contraindicated in patients with diabetes mellitus or renal impairment (GFR &lt;60 ml/min/1.73 m&sup2;) (see<br />Section 4.5).<br />Hepatic impairment: thiazides should be used with caution in patients with impaired hepatic function or<br />progressive liver disease, since minor alterations of fluid and electrolyte balance may precipitate hepatic<br />coma. There is no clinical experience with Cigavel Plus in patients with hepatic impairment.<br />Aortic and mitral valve stenosis, obstructive hypertrophic cardiomyopathy: as with other vasodilators,<br />special caution is indicated in patients suffering from aortic or mitral stenosis, or obstructive hypertrophic<br />cardiomyopathy.<br />Primary aldosteronism: patients with primary aldosteronism generally will not respond to antihypertensive<br />medicinal products acting through inhibition of the renin-angiotensin system. Therefore, the use of Cigavel<br />Plus is not recommended.<br />Metabolic and endocrine effects: thiazide therapy may impair glucose tolerance. In diabetic patients dosage<br />adjustments of insulin or oral hypoglycemic agents may be required. Latent diabetes mellitus may become<br />manifest during thiazide therapy.<br />Increases in cholesterol and triglyceride levels have been associated with thiazide diuretic therapy; however<br />at the 12.5 mg dose contained in Cigavel Plus, minimal or no effects were reported.<br />Hyperuricaemia may occur or frank gout may be precipitated in certain patients receiving thiazide therapy.<br />Electrolyte imbalance: as for any patient receiving diuretic therapy, periodic determination of serum<br />electrolytes should be performed at appropriate intervals.<br />Thiazides, including hydrochlorothiazide, can cause fluid or electrolyte imbalance (hypokalaemia,<br />hyponatraemia, and hypochloremic alkalosis). Warning signs of fluid or electrolyte imbalance are dryness<br />of mouth, thirst, weakness, lethargy, drowsiness, restlessness, muscle pain or cramps, muscular fatigue,<br />hypotension, oliguria, tachycardia, and gastrointestinal disturbances such as nausea or vomiting.<br />Although hypokalaemia may develop with the use of thiazide diuretics, concurrent therapy with irbesartan<br />may reduce diuretic-induced hypokalaemia.<br />The risk of hypokalaemia is greatest in patients with cirrhosis of the liver, in patients experiencing brisk<br />diuresis, in patients who are receiving inadequate oral intake of electrolytes and in patients receiving<br />concomitant therapy with corticosteroids or ACTH. Conversely, due to the irbesartan component of<br />Cigavel Plus hyperkalaemia might occur, especially in the presence of renal impairment and/or heart<br />failure, and diabetes mellitus. Adequate monitoring of serum potassium in patients at risk is recommended.<br />Potassium-sparing diuretics, potassium supplements or potassium-containing salts substitutes should be coadministered<br />cautiously with Cigavel Plus (see section 4.5).<br />There is no evidence that irbesartan would reduce or prevent diuretic-induced hyponatraemia. Chloride<br />deficit is generally mild and usually does not require treatment.<br />Thiazides may decrease urinary calcium excretion and cause an intermittent and slight elevation of serum<br />calcium in the absence of known disorders of calcium metabolism. Marked hypercalcaemia may be<br />evidence of hidden hyperparathyroidism. Thiazides should be discontinued before carrying out tests for<br />parathyroid function.<br />Thiazides have been shown to increase the urinary excretion of magnesium, which may result in<br />hypomagnaesemia.<br />Lithium: the combination of lithium and Cigavel Plus is not recommended (see section 4.5).<br />Anti-doping test: hydrochlorothiazide contained in this medicinal product could produce a positive analytic<br />result in an anti-doping test.<br />General: in patients whose vascular tone and renal function depend predominantly on the activity of the<br />renin-angiotensin-aldosterone system (e.g. patients with severe congestive heart failure or underlying renal<br />disease, including renal artery stenosis), treatment with angiotensin converting enzyme inhibitors or<br />angiotensin-II receptor antagonists that affect this system has been associated with acute hypotension,<br />azotemia, oliguria, or rarely acute renal failure (see section 4.5). As with any antihypertensive agent,<br />excessive blood pressure decrease in patients with ischemic cardiopathy or ischemic cardiovascular disease<br />could result in a myocardial infarction or stroke.<br />Hypersensitivity reactions to hydrochlorothiazide may occur in patients with or without a history of allergy<br />or bronchial asthma, but are more likely in patients with such a history.<br />Exacerbation or activation of systemic lupus erythematosus has been reported with the use of thiazide<br />diuretics.<br />Cases of photosensitivity reactions have been reported with thiazides diuretics (see section 4.8). If<br />photosensitivity reaction occurs during treatment, it is recommended to stop the treatment. If a readministration<br />of the diuretic is deemed necessary, it is recommended to protect exposed areas to the sun or<br />to artificial UVA.<br />Pregnancy: Angiotensin II Receptor Antagonists (AIIRAs) should not be initiated during pregnancy. Unless<br />continued AIIRA therapy is considered essential, patients planning pregnancy should be changed to<br />alternative antihypertensive treatments which have an established safety profile for use in pregnancy. When<br />pregnancy is diagnosed, treatment with AIIRAs should be stopped immediately, and, if appropriate,<br />alternative therapy should be started (see sections 4.3 and 4.6).<br />Lactose: this medicinal product contains lactose. Patients with rare hereditary problems of galactose<br />intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicinal<br />product.<br />Acute Myopia and Secondary Acute Angle-Closure Glaucoma: sulfonamide drugs or sulfonamide<br />derivative drugs can cause an idiosyncratic reaction, resulting in transient myopia and acute angle-closure<br />glaucoma. While hydrochlorothiazide is a sulfonamide, only isolated cases of acute angle-closure glaucoma<br />have been reported so far with hydrochlorothiazide. Symptoms include acute onset of decreased visual<br />acuity or ocular pain and typically occur within hours to weeks of drug initiation. Untreated acute angleclosure<br />glaucoma can lead to permanent vision loss. The primary treatment is to discontinue drug intake as<br />rapidly as possible. Prompt medical or surgical treatments may need to be considered if the intraocular<br />pressure remains uncontrolled. Risk factors for developing acute angle-closure glaucoma may include a<br />history of sulfonamide or penicillin allergy (see section 4.8).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:left">Other antihypertensive agents: the antihypertensive effect of Cigavel Plus may be increased with the<br />concomitant use of other antihypertensive agents. Irbesartan and hydrochlorothiazide (at doses up to 300<br />mg irbesartan/25 mg hydrochlorothiazide) have been safely administered with other antihypertensive<br />agents including calcium channel blockers and beta-adrenergic blockers. Prior treatment with high dose<br />diuretics may result in volume depletion and a risk of hypotension when initiating therapy with irbesartan<br />with or without thiazide diuretics unless the volume depletion is corrected first (see section 4.4).<br />Aliskiren-containing products: the combination of Cigavel Plus with aliskiren-containing medicinal<br />products is contraindicated in patients with diabetes mellitus or moderate to severe renal impairment (GFR<br />&lt;60 ml/min/1.73 m&sup2;) and is not recommended in other patients.<br />Lithium: reversible increases in serum lithium concentrations and toxicity have been reported during<br />concomitant administration of lithium with angiotensin converting enzyme inhibitors. Similar effects have<br />been very rarely reported with irbesartan so far. Furthermore, renal clearance of lithium is reduced by<br />thiazides so the risk of lithium toxicity could be increased with Cigavel Plus. Therefore, the combination of<br />lithium and Cigavel Plus is not recommended (see section 4.4). If the combination proves necessary,<br />careful monitoring of serum lithium levels is recommended.<br />Medicinal products affecting potassium: the potassium-depleting effect of hydrochlorothiazide is attenuated<br />by the potassium-sparing effect of irbesartan. However, this effect of hydrochlorothiazide on serum<br />potassium would be expected to be potentiated by other medicinal products associated with potassium loss<br />and hypokalaemia (e.g. other kaliuretic diuretics, laxatives, amphotericin, carbenoxolone, penicillin G<br />sodium). Conversely, based on the experience with the use of other medicinal products that blunt the reninangiotensin<br />system, concomitant use of potassium-sparing diuretics, potassium supplements, salt substitutes<br />containing potassium or other medicinal products that may increase serum potassium levels (e.g. heparin<br />sodium) may lead to increases in serum potassium. Adequate monitoring of serum potassium in patients at<br />risk is recommended (see section 4.4).<br />Medicinal products affected by serum potassium disturbances: periodic monitoring of serum potassium is<br />recommended when Cigavel Plus is administered with medicinal products affected by serum potassium<br />disturbances (e.g. digitalis glycosides, antiarrhythmics).<br />Non-steroidal anti-inflammatory drugs: when angiotensin II antagonists are administered simultaneously<br />with non-steroidal anti- inflammatory drugs (i.e. selective COX-2 inhibitors, acetylsalicylic acid (&gt; 3<br />g/day) and non-selective NSAIDs), attenuation of the antihypertensive effect may occur.<br />As with ACE inhibitors, concomitant use of angiotensin II antagonists and NSAIDs may lead to an<br />increased risk of worsening of renal function, including possible acute renal failure, and an increase in<br />serum potassium, especially in patients with poor pre-existing renal function. The combination should be<br />administered with caution, especially in the elderly. Patients should be adequately hydrated and<br />consideration should be given to monitoring renal function after initiation of concomitant therapy, and<br />periodically thereafter.<br />Additional information on irbesartan interactions: in clinical studies, the pharmacokinetic of irbesartan is<br />not affected by hydrochlorothiazide. Irbesartan is mainly metabolised by CYP2C9 and to a lesser extent by<br />glucuronidation. No significant pharmacokinetic or pharmacodynamic interactions were observed when<br />irbesartan was coadministered with warfarin, a medicinal product metabolised by CYP2C9. The effects of<br />CYP2C9 inducers such as rifampicin on the pharmacokinetic of irbesartan have not been evaluated. The<br />pharmacokinetic of digoxin was not altered by co-administration of irbesartan.<br />Additional information on hydrochlorothiazide interactions: when administered concurrently, the following<br />medicinal products may interact with thiazide diuretics:<br />Alcohol: potentiation of orthostatic hypotension may occur;<br />Antidiabetic medicinal products (oral agents and insulins): dosage adjustment of the antidiabetic medicinal<br />product may be required (see section 4.4);<br />Colestyramine and Colestipol resins: absorption of hydrochlorothiazide is impaired in the presence of<br />anionic exchange resins. Cigavel Plus should be taken at least one hour before or four hours after these<br />medications;<br />Corticosteroids, ACTH: electrolyte depletion, particularly hypokalaemia, may be increased;<br />Digitalis glycosides: thiazide induced hypokalaemia or hypomagnaesemia favour the onset of digitalisinduced<br />cardiac arrhythmias (see section 4.4);<br />Non-steroidal anti-inflammatory drugs: the administration of a non-steroidal anti-inflammatory drug may<br />reduce the diuretic, natriuretic and antihypertensive effects of thiazide diuretics in some patients;<br />Pressor amines (e.g. noradrenaline): the effect of pressor amines may be decreased, but not sufficiently to<br />preclude their use;<br />Nondepolarizing skeletal muscle relaxants (e.g. tubocurarine): the effect of nondepolarizing skeletal<br />muscle relaxants may be potentiated by hydrochlorothiazide;<br />Antigout medicinal products: dosage adjustments of antigout medicinal products may be necessary as<br />hydrochlorothiazide may raise the level of serum uric acid. Increase in dosage of probenecid or<br />sulfinpyrazone may be necessary. Co-administration of thiazide diuretics may increase the incidence of<br />hypersensitivity reactions to allopurinol;<br />Calcium salts: thiazide diuretics may increase serum calcium levels due to decreased excretion. If calcium<br />supplements or calcium sparing medicinal products (e.g. vitamin D therapy) must be prescribed, serum<br />calcium levels should be monitored and calcium dosage adjusted accordingly;<br />Carbamazepine: concomitant use of carbamazepine and hydrochlorothiazide has been associated with the<br />risk of symptomatic hyponatraemia. Electrolytes should be monitored during concomitant use. If possible,<br />another class of diuretics should be used;<br />Other interactions: the hyperglycaemic effect of beta-blockers and diazoxide may be enhanced by<br />thiazides. Anticholinergic agents (e.g. atropine, beperiden) may increase the bioavailability of thiazide-type<br />diuretics by decreasing gastrointestinal motility and stomach emptying rate. Thiazides may increase the risk<br />of adverse effects caused by amantadine. Thiazides may reduce the renal excretion of cytotoxic medicinal<br />products (e.g. cyclophosphamide, methotrexate) and potentiate their myelosuppressive effects.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:left">Pregnancy:<br />Angiotensin II Receptor Antagonists (AIIRAs):<br />The use of AIIRAs is not recommended during the first trimester of pregnancy (see section 4.4). The<br />use of AIIRAs is contraindicated during the second and third trimesters of pregnancy (see sections<br />4.3 and 4.4).<br />Pregnancy category D<br />Hydrochlorothiazide (HCTZ)-irbesartan has been assigned to pregnancy category D by the FDA. Animal<br />data have revealed evidence of fetotoxicity associated with the use of irbesartan (renal pelvic cavitation,<br />hydroureter and/or absence of renal papilla) after doses equivalent to maximum recommended human doses<br />(MRHD) and maternal mortality and abortion after doses equivalent to 1.5 times the MRHD after<br />correction for body surface area. Surviving females receiving 1.5 times the MRHD were observed to have<br />an increased incidence of early fetal resorptions and a corresponding decrease in live births. There are no<br />controlled data in human pregnancy. The manufacturer states that when used in pregnancy during the<br />second and third trimesters, drugs that act directly on the renin-angiotensin system can cause injury and<br />even death to the developing fetus.<br />Retrospective reviews have shown an increased risk of malformations associated with thiazide diuretics.<br />Use of HCTZ-irbesartan is considered contraindicated during pregnancy.<br />Epidemiological evidence regarding the risk of teratogenicity following exposure to ACE inhibitors during<br />the first trimester of pregnancy has not been conclusive; however a small increase in risk cannot be<br />excluded. Whilst there is no controlled epidemiological data on the risk with Angiotensin II Receptor<br />Antagonists (AIIRAs), similar risks may exist for this class of drugs. Unless continued AIIRA therapy is<br />considered essential, patients planning pregnancy should be changed to alternative antihypertensive<br />treatments which have an established safety profile for use in pregnancy. When pregnancy is diagnosed,<br />treatment with AIIRAs should be stopped immediately, and, if appropriate, alternative therapy should be<br />started.<br />Exposure to AIIRA therapy during the second and third trimesters is known to induce human fetotoxicity<br />(decreased renal function, oligohydramnios, skull ossification retardation) and neonatal toxicity (renal<br />failure, hypotension, hyperkalaemia). (See section 5.3).<br />Should exposure to AIIRAs have occurred from the second trimester of pregnancy, ultrasound check of<br />renal function and skull is recommended.<br />Infants whose mothers have taken AIIRAs should be closely observed for hypotension (see sections 4.3 and<br />4.4).<br />Hydrochlorothiazide:<br />There is limited experience with hydrochlorothiazide during pregnancy, especially during the first<br />trimester. Animal studies are insufficient. Hydrochlorothiazide crosses the placenta. Based on the<br />pharmacological mechanism of action of hydrochlorothiazide its use during the second and third trimester<br />may compromise foeto-placental perfusion and may cause foetal and neonatal effects like icterus,<br />disturbance of electrolyte balance and thrombocytopenia.<br />Hydrochlorothiazide should not be used for gestational oedema, gestational hypertension or preeclampsia<br />due to the risk of decreased plasma volume and placental hypoperfusion, without a beneficial effect on the<br />course of the disease.<br />Hydrochlorothiazide should not be used for essential hypertension in pregnant women except in rare<br />situations where no other treatment could be used.<br />Since Cigavel Plus contains hydrochlorothiazide, it is not recommended during the first trimester of<br />pregnancy. A switch to a suitable alternative treatment should be carried out in advance of a planned<br />pregnancy.<br />Breast-feeding:<br />Angiotensin II Receptor Antagonists (AIIRAs):<br />Because no information is available regarding the use of Cigavel Plus during breast-feeding, Cigavel Plus<br />is not recommended and alternative treatments with better established safety profiles during breast-feeding<br />are preferable, especially while nursing a newborn or preterm infant.<br />It is unknown whether irbesartan or its metabolites are excreted in human milk.<br />Available pharmacodynamic/toxicological data in rats have shown excretion of irbesartan or its metabolites<br />in milk (for details see 5.3).<br />Hydrochlorothiazide:<br />Hydrochlorothiazide is excreted in human milk in small amounts. Thiazides in high doses causing intense<br />diuresis can inhibit the milk production. The use of Cigavel Plus during breast feeding is not recommended.<br />If Cigavel Plus is used during breast feeding, doses should be kept as low as possible.<br />Fertility:<br />Irbesartan had no effect upon fertility of treated rats and their offspring up to the dose levels inducing the<br />first signs of parental toxicity (see section 5.3).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:left">No studies on the effects on the ability to drive and use machines have been performed. Based on its<br />pharmacodynamic properties, Cigavel Plus is unlikely to affect this ability. When driving vehicles or<br />operating machines, it should be taken into account that occasionally dizziness or weariness may occur<br />during treatment of hypertension.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:left">Irbesartan/hydrochlorothiazide combination:<br />Among 898 hypertensive patients who received various doses of irbesartan/hydrochlorothiazide (range:<br />37.5 mg/6.25 mg to 300 mg/25 mg) in placebo-controlled trials, 29.5% of the patients experienced adverse<br />reactions. The most commonly reported ADRs were dizziness (5.6%), fatigue (4.9%), nausea/vomiting<br />(1.8%), and abnormal urination (1.4%). In addition, increases in blood urea nitrogen (BUN) (2.3%),<br />creatine kinase (1.7%) and creatinine (1.1%) were also commonly observed in the trials.<br />Table 1 gives the adverse reactions observed from spontaneous reporting and in placebo-controlled trials.<br />The frequency of adverse reactions listed below is defined using the following convention:<br />very common (&ge; 1/10); common (&ge; 1/100 to &lt; 1/10); uncommon (&ge; 1/1,000 to &lt; 1/100); rare (&ge; 1/10,000 to<br />&lt; 1/1,000); very rare (&lt; 1/10,000). Within each frequency grouping, undesirable effects are presented in<br />order of decreasing seriousness.</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="height:21.65pt; vertical-align:top; width:462.15pt" colspan="3"><p style="margin-left:2.75pt; margin-right:0cm; text-align:left"><strong>Table 1: </strong>Adverse Reactions in Placebo-Controlled Trials and Spontaneous Reports</p></td></tr><tr><td style="height:34.25pt; vertical-align:top; width:184.85pt" rowspan="2"><p style="margin-left:2.75pt; margin-right:0cm; text-align:left"><em>Investigations:</em></p></td><td style="height:34.25pt; vertical-align:top; width:92.5pt"><p style="text-align:left">Common:</p></td><td style="height:34.25pt; vertical-align:top; width:184.8pt"><p style="margin-right:4.55pt; text-align:left">increases in blood urea nitrogen (BUN), creatinine and creatine kinase</p></td></tr><tr><td style="height:34.3pt; vertical-align:top; width:92.5pt"><p style="text-align:left">Uncommon:</p></td><td style="height:34.3pt; vertical-align:top; width:184.8pt"><p style="margin-right:22.8pt; text-align:left">decreases in serum potassium and sodium</p></td></tr><tr><td style="height:34.25pt; vertical-align:top; width:184.85pt"><p style="margin-left:2.75pt; margin-right:0cm; text-align:left"><em>Cardiac disorders:</em></p></td><td style="height:34.25pt; vertical-align:top; width:92.5pt"><p style="text-align:left">Uncommon:</p></td><td style="height:34.25pt; vertical-align:top; width:184.8pt"><p style="margin-right:4.55pt; text-align:left">syncope, hypotension, tachycardia, oedema</p></td></tr><tr><td style="height:21.3pt; vertical-align:top; width:184.85pt" rowspan="3"><p style="margin-left:2.75pt; margin-right:0cm; text-align:left"><em>Nervous system disorders:</em></p></td><td style="height:21.3pt; vertical-align:top; width:92.5pt"><p style="text-align:left">Common:</p></td><td style="height:21.3pt; vertical-align:top; width:184.8pt"><p style="margin-left:3pt; margin-right:0cm; text-align:left">dizziness</p></td></tr><tr><td style="height:21.3pt; vertical-align:top; width:92.5pt"><p style="text-align:left">Uncommon:</p></td><td style="height:21.3pt; vertical-align:top; width:184.8pt"><p style="margin-left:3pt; text-align:left">orthostatic dizziness</p></td></tr><tr><td style="height:21.3pt; vertical-align:top; width:92.5pt"><p style="text-align:left">Not known:</p></td><td style="height:21.3pt; vertical-align:top; width:184.8pt"><p style="margin-left:3pt; text-align:left">headache</p></td></tr><tr><td style="height:21.7pt; vertical-align:top; width:184.85pt"><p style="margin-left:2.75pt; margin-right:0cm; text-align:left"><em>Ear and labyrinth disorders:</em></p></td><td style="height:21.7pt; vertical-align:top; width:92.5pt"><p style="text-align:left">Not known:</p></td><td style="height:21.7pt; vertical-align:top; width:184.8pt"><p style="margin-left:3pt; text-align:left">tinnitus</p></td></tr></tbody></table><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="height:34.65pt; vertical-align:top; width:184.85pt"><p style="margin-left:2.75pt; margin-right:3.8pt; text-align:left"><em>Respiratory, thoracic and mediastinal disorders:</em></p></td><td style="height:34.65pt; vertical-align:top; width:92.5pt"><p style="text-align:left">Not known:</p></td><td style="height:34.65pt; vertical-align:top; width:184.8pt"><p style="text-align:left">cough</p></td></tr><tr><td style="height:21.3pt; vertical-align:top; width:184.85pt" rowspan="3"><p style="margin-left:2.75pt; margin-right:0cm; text-align:left"><em>Gastrointestinal disorders:</em></p></td><td style="height:21.3pt; vertical-align:top; width:92.5pt"><p style="text-align:left">Common:</p></td><td style="height:21.3pt; vertical-align:top; width:184.8pt"><p style="margin-left:3pt; margin-right:0cm; text-align:left">nausea/vomiting</p></td></tr><tr><td style="height:21.25pt; vertical-align:top; width:92.5pt"><p style="text-align:left">Uncommon:</p></td><td style="height:21.25pt; vertical-align:top; width:184.8pt"><p style="margin-left:3pt; text-align:left">diarrhoea</p></td></tr><tr><td style="height:21.35pt; vertical-align:top; width:92.5pt"><p style="text-align:left">Not known:</p></td><td style="height:21.35pt; vertical-align:top; width:184.8pt"><p style="text-align:left">dyspepsia, dysgeusia</p></td></tr><tr><td style="height:21.25pt; vertical-align:top; width:184.85pt" rowspan="2"><p style="margin-left:2.75pt; margin-right:0cm; text-align:left"><em>Renal and urinary disorders:</em></p></td><td style="height:21.25pt; vertical-align:top; width:92.5pt"><p style="text-align:left">Common:</p></td><td style="height:21.25pt; vertical-align:top; width:184.8pt"><p style="margin-left:3pt; text-align:left">abnormal urination</p></td></tr><tr><td style="height:47.3pt; vertical-align:top; width:92.5pt"><p style="text-align:left">Not known:</p></td><td style="height:47.3pt; vertical-align:top; width:184.8pt"><p style="margin-left:2.95pt; margin-right:24.4pt; text-align:left">impaired renal function including isolated cases of renal failure in patients at risk (see section 4.4)</p></td></tr><tr><td style="height:21.25pt; vertical-align:top; width:184.85pt" rowspan="2"><p style="margin-left:2.75pt; margin-right:2.85pt; text-align:left"><em>Musculoskeletal and connective tissue disorders:</em></p></td><td style="height:21.25pt; vertical-align:top; width:92.5pt"><p style="text-align:left">Uncommon:</p></td><td style="height:21.25pt; vertical-align:top; width:184.8pt"><p style="margin-left:3pt; text-align:left">swelling extremity</p></td></tr><tr><td style="height:21.35pt; vertical-align:top; width:92.5pt"><p style="text-align:left">Not known:</p></td><td style="height:21.35pt; vertical-align:top; width:184.8pt"><p style="text-align:left">arthralgia, myalgia</p></td></tr><tr><td style="height:21.25pt; vertical-align:top; width:184.85pt"><p style="margin-left:2.75pt; margin-right:0cm; text-align:left"><em>Metabolism and nutrition disorders:</em></p></td><td style="height:21.25pt; vertical-align:top; width:92.5pt"><p style="text-align:left">Not known:</p></td><td style="height:21.25pt; vertical-align:top; width:184.8pt"><p style="margin-left:3pt; text-align:left">hyperkalaemia</p></td></tr><tr><td style="height:21.35pt; vertical-align:top; width:184.85pt"><p style="margin-left:2.75pt; margin-right:0cm; text-align:left"><em>Vascular disorders:</em></p></td><td style="height:21.35pt; vertical-align:top; width:92.5pt"><p style="text-align:left">Uncommon:</p></td><td style="height:21.35pt; vertical-align:top; width:184.8pt"><p style="margin-left:3pt; margin-right:0cm; text-align:left">flushing</p></td></tr><tr><td style="height:34.25pt; vertical-align:top; width:184.85pt"><p style="margin-left:2.75pt; margin-right:4.1pt; text-align:left"><em>General disorders and administration site conditions:</em></p></td><td style="height:34.25pt; vertical-align:top; width:92.5pt"><p style="text-align:left">Common:</p></td><td style="height:34.25pt; vertical-align:top; width:184.8pt"><p style="margin-left:3pt; margin-right:0cm; text-align:left">fatigue</p></td></tr><tr><td style="height:34.3pt; vertical-align:top; width:184.85pt"><p style="margin-left:2.75pt; margin-right:0cm; text-align:left"><em>Immune system disorders:</em></p></td><td style="height:34.3pt; vertical-align:top; width:92.5pt"><p style="text-align:left">Not known:</p></td><td style="height:34.3pt; vertical-align:top; width:184.8pt"><p style="margin-left:2.95pt; margin-right:17.7pt; text-align:left">cases of hypersensitivity reactions such as angioedema, rash, urticaria</p></td></tr><tr><td style="height:47.4pt; vertical-align:top; width:184.85pt"><p style="margin-left:2.75pt; margin-right:0cm; text-align:left"><em>Hepatobiliary disorders:</em></p></td><td style="height:47.4pt; vertical-align:top; width:92.5pt"><p style="text-align:left">Uncommon:</p><p style="margin-left:0cm; margin-right:0cm; text-align:left">&nbsp;</p><p style="text-align:left">Not known:</p></td><td style="height:47.4pt; vertical-align:top; width:184.8pt"><p style="text-align:left">jaundice</p><p style="margin-left:0cm; margin-right:0cm; text-align:left">&nbsp;</p><p style="text-align:left">hepatitis, abnormal liver function</p></td></tr><tr><td style="height:34.65pt; vertical-align:top; width:184.85pt"><p style="margin-left:2.75pt; margin-right:32.35pt; text-align:left"><em>Reproductive system and breast disorders:</em></p></td><td style="height:34.65pt; vertical-align:top; width:92.5pt"><p style="text-align:left">Uncommon:</p></td><td style="height:34.65pt; vertical-align:top; width:184.8pt"><p style="margin-left:3pt; margin-right:0cm; text-align:left">sexual dysfunction, libido changes</p></td></tr></tbody></table><p style="margin-left:22.4pt; margin-right:15pt; text-align:left"><u>Additional information on individual components:</u> in addition to the adverse reactions listed above for the combination product, other adverse reactions previously reported with one of the individual components may be potential adverse reactions with Cigavel Plus. Tables 2 and 3 below detail the adverse reactions reported with the individual components of Cigavel Plus.</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="height:21.65pt; vertical-align:top; width:462.15pt" colspan="3"><p style="margin-left:2.75pt; margin-right:0cm; text-align:left"><strong>Table 2: </strong>Adverse reactions reported with the use of <strong>irbesartan </strong>alone</p></td></tr><tr><td style="height:34.65pt; vertical-align:top; width:184.85pt"><p style="margin-left:2.75pt; margin-right:4.1pt; text-align:left"><em>General disorders and administration site conditions:</em></p></td><td style="height:34.65pt; vertical-align:top; width:92.5pt"><p style="text-align:left">Uncommon:</p></td><td style="height:34.65pt; vertical-align:top; width:184.8pt"><p style="text-align:left">chest pain</p></td></tr><tr><td style="height:22.0pt; vertical-align:top; width:462.15pt" colspan="3"><p style="margin-left:2.75pt; text-align:left"><strong>Table 3: </strong>Adverse reactions reported with the use of <strong>hydrochlorothiazide </strong>alone</p></td></tr></tbody></table><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="height:73.6pt; vertical-align:top; width:184.85pt"><p style="margin-left:2.75pt; margin-right:0cm; text-align:left"><em>Investigations:</em></p></td><td style="height:73.6pt; vertical-align:top; width:92.5pt"><p style="text-align:left">Not known:</p></td><td style="height:73.6pt; vertical-align:top; width:184.8pt"><p style="margin-left:2.95pt; margin-right:2.95pt; text-align:left; text-indent:-0.05pt">electrolyte imbalance (including hypokalaemia and hyponatraemia, see section 4.4), hyperuricaemia, glycosuria, hyperglycaemia, increases in cholesterol and triglycerides</p></td></tr><tr><td style="height:21.35pt; vertical-align:top; width:184.85pt"><p style="margin-left:2.75pt; margin-right:0cm; text-align:left"><em>Cardiac disorders:</em></p></td><td style="height:21.35pt; vertical-align:top; width:92.5pt"><p style="text-align:left">Not known:</p></td><td style="height:21.35pt; vertical-align:top; width:184.8pt"><p style="margin-left:3pt; margin-right:0cm; text-align:left">cardiac arrhythmias</p></td></tr><tr><td style="height:73.2pt; vertical-align:top; width:184.85pt"><p style="margin-left:2.75pt; text-align:left"><em>Blood and lymphatic system disorders:</em></p></td><td style="height:73.2pt; vertical-align:top; width:92.5pt"><p style="text-align:left">Not known:</p></td><td style="height:73.2pt; vertical-align:top; width:184.8pt"><p style="margin-left:2.95pt; margin-right:27.95pt; text-align:left; text-indent:-0.05pt">aplastic anaemia, bone marrow depression, neutropenia/agranulocytosis, haemolytic anaemia, leucopenia, thrombocytopenia</p></td></tr><tr><td style="height:60.4pt; vertical-align:top; width:184.85pt"><p style="margin-left:2.75pt; margin-right:0cm; text-align:left"><em>Nervous system disorders:</em></p></td><td style="height:60.4pt; vertical-align:top; width:92.5pt"><p style="text-align:left">Not known:</p></td><td style="height:60.4pt; vertical-align:top; width:184.8pt"><p style="margin-right:4.55pt; text-align:left">vertigo, paraesthesia, light-headedness, restlessness</p></td></tr><tr><td style="height:47.25pt; vertical-align:top; width:184.85pt"><p style="margin-left:2.75pt; margin-right:0cm; text-align:left"><em>Eye disorders:</em></p></td><td style="height:47.25pt; vertical-align:top; width:92.5pt"><p style="text-align:left">Not known:</p></td><td style="height:47.25pt; vertical-align:top; width:184.8pt"><p style="margin-right:14.35pt; text-align:left">transient blurred vision, xanthopsia, acute myopia and secondary acute angle-closure glaucoma</p></td></tr><tr><td style="height:34.35pt; vertical-align:top; width:184.85pt"><p style="margin-left:2.75pt; margin-right:3.8pt; text-align:left"><em>Respiratory, thoracic and mediastinal disorders:</em></p></td><td style="height:34.35pt; vertical-align:top; width:92.5pt"><p style="text-align:left">Not known:</p></td><td style="height:34.35pt; vertical-align:top; width:184.8pt"><p style="margin-left:2.95pt; margin-right:7.1pt; text-align:left">respiratory distress (including pneumonitis and pulmonary oedema)</p></td></tr><tr><td style="height:47.25pt; vertical-align:top; width:184.85pt"><p style="margin-left:2.75pt; text-align:left"><em>Gastrointestinal disorders:</em></p></td><td style="height:47.25pt; vertical-align:top; width:92.5pt"><p style="text-align:left">Not known:</p></td><td style="height:47.25pt; vertical-align:top; width:184.8pt"><p style="margin-left:2.95pt; margin-right:1cm; text-align:left; text-indent:-0.05pt">pancreatitis, anorexia, diarrhoea, constipation, gastric irritation, sialadenitis, loss of appetite</p></td></tr><tr><td style="height:21.3pt; vertical-align:top; width:184.85pt"><p style="margin-left:2.75pt; margin-right:0cm; text-align:left"><em>Renal and urinary disorders:</em></p></td><td style="height:21.3pt; vertical-align:top; width:92.5pt"><p style="text-align:left">Not known:</p></td><td style="height:21.3pt; vertical-align:top; width:184.8pt"><p style="margin-left:3pt; text-align:left">interstitial nephritis, renal dysfunction</p></td></tr><tr><td style="height:99.2pt; vertical-align:top; width:184.85pt"><p style="margin-left:2.75pt; margin-right:44.5pt; text-align:left"><em>Skin and subcutaneous tissue disorders:</em></p></td><td style="height:99.2pt; vertical-align:top; width:92.5pt"><p style="text-align:left">Not known:</p></td><td style="height:99.2pt; vertical-align:top; width:184.8pt"><p style="margin-right:3.1pt; text-align:left">anaphylactic reactions, toxic epidermal necrolysis, necrotizing angitis (vasculitis, cutaneous vasculitis), cutaneous lupus erythematosus-like reactions, reactivation of cutaneous lupus erythematosus, photosensitivity reactions, rash, urticaria</p></td></tr><tr><td style="height:34.65pt; vertical-align:top; width:184.85pt"><p style="margin-left:2.75pt; margin-right:2.85pt; text-align:left"><em>Musculoskeletal and connective tissue disorders:</em></p></td><td style="height:34.65pt; vertical-align:top; width:92.5pt"><p style="text-align:left">Not known:</p></td><td style="height:34.65pt; vertical-align:top; width:184.8pt"><p style="text-align:left">weakness, muscle spasm</p></td></tr><tr><td style="height:21.65pt; vertical-align:top; width:184.85pt"><p style="margin-left:2.75pt; margin-right:0cm; text-align:left"><em>Vascular disorders:</em></p></td><td style="height:21.65pt; vertical-align:top; width:92.5pt"><p style="text-align:left">Not known:</p></td><td style="height:21.65pt; vertical-align:top; width:184.8pt"><p style="text-align:left">postural hypotension</p></td></tr><tr><td style="height:34.65pt; vertical-align:top; width:184.85pt"><p style="margin-left:2.75pt; margin-right:4.1pt; text-align:left"><em>General disorders and administration site conditions:</em></p></td><td style="height:34.65pt; vertical-align:top; width:92.5pt"><p style="text-align:left">Not known:</p></td><td style="height:34.65pt; vertical-align:top; width:184.8pt"><p style="text-align:left">fever</p></td></tr><tr><td style="height:35.0pt; vertical-align:top; width:184.85pt"><p style="margin-left:2.75pt; margin-right:0cm; text-align:left"><em>Hepatobiliary disorders:</em></p></td><td style="height:35.0pt; vertical-align:top; width:92.5pt"><p style="text-align:left">Not known:</p></td><td style="height:35.0pt; vertical-align:top; width:184.8pt"><p style="margin-left:2.95pt; margin-right:26.8pt; text-align:left; text-indent:-0.1pt">jaundice (intrahepatic cholestatic jaundice)</p></td></tr></tbody></table><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="border-color:#a0a0a0; height:22.1pt; vertical-align:top; width:184.85pt"><p style="margin-left:2.75pt; margin-right:0cm; text-align:left"><em>Psychiatric disorders:</em></p></td><td style="border-color:#a0a0a0; height:22.1pt; vertical-align:top; width:92.5pt"><p style="text-align:left">Not known:</p></td><td style="border-color:#a0a0a0; height:22.1pt; vertical-align:top; width:184.8pt"><p style="margin-left:3pt; margin-right:0cm; text-align:left">depression, sleep disturbances</p></td></tr></tbody></table><p style="margin-left:22.4pt; margin-right:15pt; text-align:left">The dose dependent adverse events of hydrochlorothiazide (particularly electrolyte disturbances) may<br />increase when titrating the hydrochlorothiazide.<br />To report any side effects<br />National Pharmacovigilance &amp; Drug Safety Centre (NPC)<br />Fax: +966-11-205-7662<br />Call NPC at: +966-11-2038222, Exts: 2317-2356-2353-2354-2334-2340.<br />Toll free phone: 8002490000<br />E-mail: npc.drug@sfda.gov.sa<br />Website: www.sfda.gov.sa/npc</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:left">No specific information is available on the treatment of overdose with Cigavel Plus. The patient should be<br />closely monitored, and the treatment should be symptomatic and supportive. Management depends on the<br />time since ingestion and the severity of the symptoms. Suggested measures include induction of emesis<br />and/or gastric lavage. Activated charcoal may be useful in the treatment of overdose. Serum electrolytes<br />and creatinine should be monitored frequently. If hypotension occurs, the patient should be placed in a<br />supine position, with salt and volume replacements given quickly.<br />The most likely manifestations of irbesartan overdose are expected to be hypotension and tachycardia;<br />bradycardia might also occur.<br />Overdose with hydrochlorothiazide is associated with electrolyte depletion (hypokalaemia, hypochloremia,<br />hyponatraemia) and dehydration resulting from excessive diuresis. The most common signs and symptoms<br />of overdose are nausea and somnolence. Hypokalaemia may result in muscle spasms and/or accentuate<br />cardiac arrhythmias associated with the concomitant use of digitalis glycosides or certain anti-arrhythmic<br />medicinal products.<br />Irbesartan is not removed by haemodialysis. The degree to which hydrochlorothiazide is removed by<br />haemodialysis has not been established.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:left">Pharmacotherapeutic group: angiotensin-II antagonists, combinations<br />ATC code: C09DA04.<br />Cigavel Plus is a combination of an angiotensin-II receptor antagonist, irbesartan, and a thiazide diuretic,<br />hydrochlorothiazide. The combination of these ingredients has an additive antihypertensive effect, reducing<br />blood pressure to a greater degree than either component alone.<br />Irbesartan is a potent, orally active, selective angiotensin-II receptor (AT1 subtype) antagonist. It is<br />expected to block all actions of angiotensin-II mediated by the AT1 receptor, regardless of the source or<br />route of synthesis of angiotensin-II. The selective antagonism of the angiotensin-II (AT1) receptors results<br />in increases in plasma renin levels and angiotensin-II levels, and a decrease in plasma aldosterone<br />concentration. Serum potassium levels are not significantly affected by irbesartan alone at the<br />recommended doses in patients without risk of electrolyte imbalance (see sections 4.4 and 4.5). Irbesartan<br />does not inhibit ACE (kininase-II), an enzyme which generates angiotensin-II and also degrades bradykinin<br />into inactive metabolites. Irbesartan does not require metabolic activation for its activity.<br />Hydrochlorothiazide is a thiazide diuretic. The mechanism of antihypertensive effect of thiazide diuretics is<br />not fully known. Thiazides affect the renal tubular mechanisms of electrolyte reabsorption, directly<br />increasing excretion of sodium and chloride in approximately equivalent amounts. The diuretic action of<br />hydrochlorothiazide reduces plasma volume, increases plasma renin activity, increases aldosterone<br />secretion, with consequent increases in urinary potassium and bicarbonate loss, and decreases in serum<br />potassium. Presumably through blockade of the renin-angiotensin-aldosterone system, co-administration of<br />irbesartan tends to reverse the potassium loss associated with these diuretics. With hydrochlorothiazide,<br />onset of diuresis occurs in 2 hours, and peak effect occurs at about 4 hours, while the action persists for<br />approximately 6-12 hours.<br />The combination of hydrochlorothiazide and irbesartan produces dose-related additive reductions in blood<br />pressure across their therapeutic dose ranges. The addition of 12.5 mg hydrochlorothiazide to 300 mg<br />irbesartan once daily in patients not adequately controlled on 300 mg irbesartan alone resulted in further<br />placebo-corrected diastolic blood pressure reductions at trough (24 hours post-dosing) of 6.1 mm Hg. The<br />combination of 300 mg irbesartan and 12.5 mg hydrochlorothiazide resulted in an overall placebosubtracted<br />systolic/diastolic reductions of up to 13.6/11.5 mm Hg.<br />Limited clinical data (7 out of 22 patients) suggest that patients not controlled with the 300 mg/12.5 mg<br />combination may respond when uptitrated to 300 mg/25 mg. In these patients, an incremental blood<br />pressure lowering effect was observed for both systolic blood pressure (SBP) and diastolic blood pressure<br />(DBP) (13.3 and 8.3 mm Hg, respectively).<br />Once daily dosing with 150 mg irbesartan and 12.5 mg hydrochlorothiazide gave systolic/diastolic mean<br />placebo-adjusted blood pressure reductions at trough (24 hours post-dosing) of 12.9/6.9 mm Hg in patients<br />with mild-to-moderate hypertension. Peak effects occurred at 3-6 hours. When assessed by ambulatory<br />blood pressure monitoring, the combination 150 mg irbesartan and 12.5 mg hydrochlorothiazide once daily<br />produced consistent reduction in blood pressure over the 24 hours period with mean 24-hour placebosubtracted<br />systolic/diastolic reductions of 15.8/10.0 mm Hg. When measured by ambulatory blood pressure<br />monitoring, the trough to peak effects of Cigavel Plus 150 mg/12.5 mg were 100%. The trough to peak<br />effects measured by cuff during office visits were 68% and 76% for Cigavel Plus 150 mg/12.5 mg and<br />Cigavel Plus 300 mg/12.5 mg, respectively. These 24-hour effects were observed without excessive blood<br />pressure lowering at peak and are consistent with safe and effective blood-pressure lowering over the oncedaily<br />dosing interval.<br />In patients not adequately controlled on 25 mg hydrochlorothiazide alone, the addition of irbesartan gave<br />an added placebo-subtracted systolic/diastolic mean reduction of 11.1/7.2 mm Hg.<br />The blood pressure lowering effect of irbesartan in combination with hydrochlorothiazide is apparent after<br />the first dose and substantially present within 1-2 weeks, with the maximal effect occurring by 6-8 weeks.<br />In long-term follow-up studies, the effect of irbesartan/hydrochlorothiazide was maintained for over one<br />year. Although not specifically studied with the Cigavel Plus, rebound hypertension has not been seen with<br />either irbesartan or hydrochlorothiazide.<br />The effect of the combination of irbesartan and hydrochlorothiazide on morbidity and mortality has not<br />been studied. Epidemiological studies have shown that long term treatment with hydrochlorothiazide<br />reduces the risk of cardiovascular mortality and morbidity.<br />There is no difference in response to Cigavel Plus, regardless of age or gender. As is the case with other<br />medicinal products that affect the renin-angiotensin system, black hypertensive patients have notably less<br />response to irbesartan monotherapy. When irbesartan is administered concomitantly with a low dose of<br />hydrochlorothiazide (e.g. 12.5 mg daily), the antihypertensive response in black patients approaches that of<br />non-black patients.<br />Efficacy and safety of Cigavel Plus as initial therapy for severe hypertension (defined as SeDBP &ge; 110<br />mmHg) was evaluated in a multicenter, randomized, double-blind, active-controlled, 8-week, parallel-arm<br />study. A total of 697 patients were randomized in a 2:1 ratio to either irbesartan/hydrochlorothiazide 150<br />mg/12.5 mg or to irbesartan 150 mg and systematically force-titrated (before assessing the response to the<br />lower dose) after one week to irbesartan/hydrochlorothiazide 300 mg/25 mg or irbesartan 300 mg,<br />respectively.<br />The study recruited 58% males. The mean age of patients was 52.5 years, 13% were &ge; 65 years of age, and<br />just 2% were &ge; 75 years of age. Twelve percent (12%) of patients were diabetic, 34% were hyperlipidemic<br />and the most frequent cardiovascular condition was stable angina pectoris in 3.5% of the participants.<br />The primary objective of this study was to compare the proportion of patients whose SeDBP was controlled<br />(SeDBP &lt; 90 mmHg) at Week 5 of treatment. Forty-seven percent (47.2%) of patients on the combination<br />achieved trough SeDBP &lt; 90 mmHg compared to 33.2% of patients on irbesartan (p = 0.0005). The mean<br />baseline blood pressure was approximately 172/113 mmHg in each treatment group and decreases of<br />SeSBP/SeDBP at five weeks were 30.8/24.0 mmHg and 21.1/19.3 mmHg for<br />irbesartan/hydrochlorothiazide and irbesartan, respectively (p &lt; 0.0001).<br />The types and incidences of adverse events reported for patients treated with the combination were similar<br />to the adverse event profile for patients on monotherapy. During the 8-week treatment period, there were<br />no reported cases of syncope in either treatment group. There were 0.6% and 0% of patients with<br />hypotension and 2.8% and 3.1% of patients with dizziness as adverse reactions reported in the combination<br />and monotherapy groups, respectively.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:left">Concomitant administration of hydrochlorothiazide and irbesartan has no effect on the pharmacokinetics of<br />either medicinal product.<br />Irbesartan and hydrochlorothiazide are orally active agents and do not require biotransformation for their<br />activity. Following oral administration of Cigavel Plus, the absolute oral bioavailability is 60-80% and 50-<br />80% for irbesartan and hydrochlorothiazide, respectively. Food does not affect the bioavailability of<br />Cigavel Plus. Peak plasma concentration occurs at 1.5-2 hours after oral administration for irbesartan and<br />1-2.5 hours for hydrochlorothiazide.<br />Plasma protein binding of irbesartan is approximately 96%, with negligible binding to cellular blood<br />components. The volume of distribution for irbesartan is 53-93 litres. Hydrochlorothiazide is 68% proteinbound<br />in the plasma, and its apparent volume of distribution is 0.83-1.14 l/kg.<br />Irbesartan exhibits linear and dose proportional pharmacokinetics over the dose range of 10 to 600 mg. A<br />less than proportional increase in oral absorption at doses beyond 600 mg was observed; the mechanism for<br />this is unknown. The total body and renal clearance are 157-176 and 3.0-3.5 ml/min, respectively. The<br />terminal elimination half-life of irbesartan is 11-15 hours. Steady-state plasma concentrations are attained<br />within 3 days after initiation of a once-daily dosing regimen. Limited accumulation of irbesartan (&lt; 20%) is<br />observed in plasma upon repeated once-daily dosing. In a study, somewhat higher plasma concentrations of<br />irbesartan were observed in female hypertensive patients. However, there was no difference in the half-life<br />and accumulation of irbesartan. No dosage adjustment is necessary in female patients. Irbesartan AUC and<br />Cmax values were also somewhat greater in older subjects (&ge; 65 years) than those of young subjects (18-40<br />years). However the terminal half-life was not significantly altered. No dosage adjustment is necessary in<br />older people. The mean plasma half-life of hydrochlorothiazide reportedly ranges from 5-15 hours.<br />Following oral or intravenous administration of 14C irbesartan, 80-85% of the circulating plasma<br />radioactivity is attributable to unchanged irbesartan. Irbesartan is metabolised by the liver via glucuronide<br />conjugation and oxidation. The major circulating metabolite is irbesartan glucuronide (approximately<br />6%). In vitro studies indicate that irbesartan is primarily oxidised by the cytochrome P450 enzyme<br />CYP2C9; isoenzyme CYP3A4 has negligible effect. Irbesartan and its metabolites are eliminated by both<br />biliary and renal pathways. After either oral or intravenous administration of 14C irbesartan, about 20% of<br />the radioactivity is recovered in the urine, and the remainder in the faeces. Less than 2% of the dose is<br />excreted in the urine as unchanged irbesartan.<br />Hydrochlorothiazide is not metabolized but is eliminated rapidly by the kidneys. At least 61% of the oral<br />dose is eliminated unchanged within 24 hours. Hydrochlorothiazide crosses the placental but not the bloodbrain<br />barrier, and is excreted in breast milk.<br />Renal impairment: in patients with renal impairment or those undergoing haemodialysis, the<br />pharmacokinetic parameters of irbesartan are not significantly altered. Irbesartan is not removed by<br />haemodialysis. In patients with creatinine clearance &lt; 20 ml/min, the elimination half-life of<br />hydrochlorothiazide was reported to increase to 21 hours.<br />Hepatic impairment: in patients with mild to moderate cirrhosis, the pharmacokinetic parameters of<br />irbesartan are not significantly altered. Studies have not been performed in patients with severe hepatic<br />impairment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:left">Irbesartan/hydrochlorothiazide: the potential toxicity of the irbesartan/hydrochlorothiazide combination<br />after oral administration was evaluated in rats and macaques in studies lasting up to 6 months. There were<br />no toxicological findings observed of relevance to human therapeutic use.<br />The following changes, observed in rats and macaques receiving the irbesartan/hydrochlorothiazide<br />combination at 10/10 and 90/90 mg/kg/day, were also seen with one of the two medicinal products alone<br />and/or were secondary to decreases in blood pressure (no significant toxicologic interactions were<br />observed):<br />&bull; kidney changes, characterized by slight increases in serum urea and creatinine, and<br />hyperplasia/hypertrophy of the juxtaglomerular apparatus, which are a direct consequence of the interaction<br />of irbesartan with the renin-angiotensin system;<br />&bull; slight decreases in erythrocyte parameters (erythrocytes, haemoglobin, haematocrit);<br />&bull; stomach discoloration, ulcers and focal necrosis of gastric mucosa were observed in few rats in a 6<br />months toxicity study at irbesartan 90 mg/kg/day, hydrochlorothiazide 90 mg/kg/day, and<br />irbesartan/hydrochlorothiazide 10/10 mg/kg/day. These lesions were not observed in macaques;<br />&bull; decreases in serum potassium due to hydrochlorothiazide and partly prevented when hydrochlorothiazide<br />was given in combination with irbesartan.<br />Most of the above mentioned effects appear to be due to the pharmacological activity of irbesartan<br />(blockade of angiotensin-II-induced inhibition of renin release, with stimulation of the renin-producing<br />cells) and occur also with angiotensin converting enzyme inhibitors. These findings appear to have no<br />relevance to the use of therapeutic doses of irbesartan/hydrochlorothiazide in humans.<br />No teratogenic effects were seen in rats given irbesartan and hydrochlorothiazide in combination at doses<br />that produced maternal toxicity. The effects of the irbesartan/hydrochlorothiazide combination on fertility<br />have not been evaluated in animal studies, as there is no evidence of adverse effect on fertility in animals or<br />humans with either irbesartan or hydrochlorothiazide when administered alone. However, another<br />angiotensin-II antagonist affected fertility parameters in animal studies when given alone. These findings<br />were also observed with lower doses of this other angiotensin-II antagonist when given in combination with<br />hydrochlorothiazide.<br />There was no evidence of mutagenicity or clastogenicity with the irbesartan/hydrochlorothiazide<br />combination. The carcinogenic potential of irbesartan and hydrochlorothiazide in combination has not been<br />evaluated in animal studies.<br />Irbesartan: there was no evidence of abnormal systemic or target organ toxicity at clinically relevant doses.<br />In non-clinical safety studies, high doses of irbesartan (&ge; 250 mg/kg/day in rats and &ge; 100 mg/kg/day in<br />macaques) caused a reduction of red blood cell parameters (erythrocytes, haemoglobin, haematocrit). At<br />very high doses (&ge; 500 mg/kg/day) degenerative changes in the kidneys (such as interstitial nephritis,<br />tubular distention, basophilic tubules, increased plasma concentrations of urea and creatinine) were induced<br />by irbesartan in the rat and the macaque and are considered secondary to the hypotensive effects of the<br />medicinal product which led to decreased renal perfusion. Furthermore, irbesartan induced<br />hyperplasia/hypertrophy of the juxtaglomerular cells (in rats at &ge; 90 mg/kg/day, in macaques at &ge; 10<br />mg/kg/day). All of these changes were considered to be caused by the pharmacological action of irbesartan.<br />For therapeutic doses of irbesartan in humans, the hyperplasia/hypertrophy of the renal juxtaglomerular<br />cells does not appear to have any relevance.<br />There was no evidence of mutagenicity, clastogenicity or carcinogenicity.<br />Fertility and reproductive performance were not affected in studies of male and female rats even at oral<br />doses of irbesartan causing some parental toxicity (from 50 to 650 mg/kg/day), including mortality at the<br />highest dose. No significant effects on the number of corpora lutea, implants, or live fetuses were observed.<br />Irbesartan did not affect survival, development, or reproduction of offspring. Studies in animals indicate<br />that the radiolabeled irbesartan is detected in rat and rabbit fetuses.<br />Irbesartan is excreted in the milk of lactating rats.<br />Animal studies with irbesartan showed transient toxic effects (increased renal pelvic cavitation, hydro<br />ureter or subcutaneous oedema) in rat fetuses, which were resolved after birth. In rabbits, abortion or early<br />resorption was noted at doses causing significant maternal toxicity, including mortality. No teratogenic<br />effects were observed in the rat or rabbit.<br />Hydrochlorothiazide: although equivocal evidence for a genotoxic or carcinogenic effect was found in<br />some experimental models, the extensive human experience with hydrochlorothiazide has failed to show an<br />association between its use and an increase in neoplasms.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:left">Lactose Monohydrate<br />Colloidal Silicon Dioxide<br />Microcrystalline Cellulose<br />Croscarmellose Sodium<br />Hypromellose 6 cps<br />Magnesium stearate<br />Opadry OY 7300<br />Ferric Oxide Red<br />Ferric Oxide Yellow<br />Simethicone Emulsion</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:left">Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                2 years.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:left">Store below 30&deg;C.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:left">Three white PVC /PVDC aluminum foil blisters each blister contains 10 tablets packed in carton with<br />folded leaflet.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:left">Any unused medicinal product or waste material should be disposed of in accordance with local<br />requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Manufacturer by Tabuk Pharmaceutical Manufacturing Co.
Astra industrial group building.
Salah Aldain Road, King abdulaziz Area.
Riyadh, Saudi Arabia
P.O.Box 28170 Riyadh 11437

Marketing by Cigalah Pharma – Jeddah.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                June 2015
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>